Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder

Pediatrics

Volumn 120, Issue 6, 2007, Pages

  Winterstein, Almut G ^a,b   Gerhard, Tobias ^a,g   Shuster, Jonathan ^b   Johnson, Michael ^c,d   Zito, Julie M ^e,f   Saidi, Arwa ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Gainesville Mental Health Partners   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g RUTGERS UNIVERSITY   (United States)

Author keywords

Attention deficit disorder; Central nervous system stimulants; Child and adolescent mental health; Pharmacoepidemiology; Psychopharmacology

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BRONCHODILATING AGENT; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PEMOLINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CHILD; CHILDHOOD MORTALITY; DRUG CLASSIFICATION; DRUG SAFETY; DRUG USE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART PALPITATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; SYNCOPE; TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES; VITAL STATISTICS;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEART DISEASES; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 36849078855     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-0675     Document Type: Article

References (33)

1. Nissen SE, ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448
2. MedPage Today Newsbrief. FDA pediatric advisers say nay to ADHD black box warning. Available at: www.medpagetoday. com/Psychiatry/ADHD-ADD/tb/2921. Accessed January 20, 2007
3. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826-1832
4. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829-835
5. Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 suppl 20):35-43
6. Samuels JA, Franco K, Wan F, et al. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92-95
7. Stowe CD, Gardner SF, Gist CC, et al. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002;36:1142-1149
8. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry. 2001;40:525-529
9. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with ADHD. J Clin Psychiatry. 2005;66:253-259
10. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118:1215-1219
11. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115(6). Available at: www.pediatrics.org/cgi/content/full/115/6/e749
12. Gelperin K, Brinker AD, Avigan MI. MedWatch reporting of death, sudden death, and cardiovascular events in association with stimulants used in the treatment of ADHD over a recent 5-year period. Available at: www.cfsan.fda.gov/~frf/forum06/I-04.htm. Accessed July 3, 2006
13. US Food and Drug Administration, Center for Drug Evaluation and Research. Alert for health professionals: Adderall and Adderall XR (amphetamine). Available at: www.fda.gov/cder/drug/InfoSheets/HCP/adderalHCP.htm. Accessed October 26, 2006
14. Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry. 2006;45:1147-1150
15. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics. 2007;119:154-155
16. Centers for Disease Control and Prevention. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54:842-847
17. Winterstein AG, Gerhard T, Shuster J, Zito JM, Johnson M, Liu H, Saidi A. Utilization of pharmacological treatment in youths with attention-deficit/ hyperactivity disorder in Florida Medicaid 1995-2004. Ann Pharmacother. In press.
18. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920
19. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 13. 2005;(158):1-199.
20. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep. 2005;53:1-89
21. Shuster, JJ. Fixing the number of events in large comparative trials with low event rates: a binomial approach. Control Clin Trials. 1993;14:198-208
22. Yeragani VK, Tancer M, Uhde T. Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res. 2003;121:185-196
23. Yeragani VK, Rao KA, Pohl R, Jampala VC, Balon R. Heart rate and QT variability in children with anxiety disorders: a preliminary report [published correction appears in Depress Anxiety. 2001;13:198]. Depress Anxiety. 2001;13:72-77
24. Lynch P, Galbraith KM. Panic in the emergency room. Can J Psychiatry. 2003;48:361-366
25. Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med. 1996;101:371-380
26. Porta M, Hartzema AG, Tilson HH. The contribution of epidemiology to the study of drug uses and effects. In: Hartzema AG, Porta M, Tilson HH, eds. Pharmacoepidemiology: An Introduction. 3rd ed. Cincinnati, OH. Harvey Whitney Books; 1998
27. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1996. Vital Health Stat 13. 1998;(134):1-37
28. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network: Development of a New Design (Methodology Report). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2002. DHHS publication (SMA) 02-3754. 2002 DAWN Series M-4
29. Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med. 2006;354:2294-2295
30. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. DHHS publication (SMA) 06-4143, DAWN Series D-28
31. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department visits involving ADHD stimulant medications. The New Dawn Report. 2006; (29). Available at: https://dawninfo.samhsa.gov/files/TNDR09ADHDmedsForHtml.pdf. Accessed November 30, 2006
32. US Food and Drug Administration. FDA News. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. Available at: www.fda.gov/bbs/topics/NEWS/2007/ NEW01568.html. Accessed March 1, 2007.
33. Nissen SE; Cardiovascular and Renal Drugs Advisory Committee. Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration: June 15-16, 2005; Gaithersburg, Md. Circulation. 2005;112:2043-2046